

APR-246 induces ferroptosis and overcomes cisplatin resistance in ovarian cancer

Ana Hernandez, Codi Mai, Shady Tantawy, Mary Ayres, Zahid Siddik, Varsha Gandhi Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center

THE UNIVERSITY OF TEXAS MDAnderson **Cancer** Center

Making Cancer History®

Background

• Ovarian cancer (OC) is the fifth deadliest cancer in women and is predicted to cause nearly

13,000 deaths in the United States in 2022. • **p53** is a well-studied tumor suppressor gene responsible for regulating the cell cycle and inducing apoptosis. Mutations in p53 are therefore associated with increased cell proliferation and aggressive forms of cancer. • 96% of high-grade serous ovarian cancers express mutations in p53.

• APR-246 is a novel small molecule thiolreactive drug, thus restoring p53 activity by targeting C277 in the protein's core domain. • APR-246 is also capable of suppressing the function of thiol-based antioxidants, such as glutathione (GSH), suggesting an ability to induce cell death by increasing intracellular reactive oxygen species (ROS). • Ferroptosis is an iron-dependent mechanism of programmed cell death characterized by lipid peroxidation due to the accumulation of ROS which may be combatted with antioxidants, such as GSH. • The mechanism by which APR-246 induces cell death in ovarian cancer is currently under study with recent data suggesting a link to ferroptosis and GSH deficiency. We have, therefore, examined this effect in p53-knockout cells to exclude p53-dependent apoptotic events.

Results: Cell Death & p53



Figure 3. APR-246 results in dose-dependent

glutathione depletion.

Figure 4. APR-246 increases ROS which was partially rescued by catalase.

Conclusions

• APR-246 induces GSH depletion associated with ferroptosis in ovarian cancer cell line A2780 as evidenced by increased lipid peroxidation and oxidative stress, which is rescued by ferroptosis inhibitors and antioxidants, respectively.

 Catalase can rescue ferroptosis by mitigating the oxidative stress necessary for



Figure 1. APR-246 is metabolized to methylene quinuclidinone (MQ) inside the cell which targets thiol groups. Cell death is caused by ferroptosis due to an increase in oxidative stress and apoptosis due to reactivation of p53.

Methods

A2780 parental and CRISPR-induced p53knockout (KO) cisplatin (CP)- resistant A2780 cell lines were used.

1) Plate cells 2) Attach cells overnight

Results: Rescue Experiments

Figure 2. APR-246 induces cell death in ovarian cancer

irrespective of p53 status.

% Cell viability (Annexin-/PI-)

%



Figure 5. Antioxidants rescue cell death induced by **APR-246.** n=2, p<0.05*, p<0.01**

Figure 6. APR-246 increases lipid peroxidation which was completely rescued by liproxstatin.

Results: Nucleotide Pool Analyses

glutamylcysteine synthetase.

control (ferroptosis inducer). Buthionine sulfoximine

(BSO) inhibits GSH synthesis by targeting γ -

Using PCA analyses, we were able to quantify the nucleotide concentration in all four A2780 cell lines according to two different doses of APR-246.

Lege	nd: 🔜 CTP(µM) 💻 UTP(µ	M) 💻	ATP(µM) 🗖 GTP(µM)	
Α	A2780 Vector Cell Line (n=3)	В	A 2780 Parental Cell line (n	1-3)
5		-	A2700 Parental Cell line (il	1-3)

lipid peroxidation which is induced by APR-246.

• APR-246 has a synergistic effect on the A2780 parental cell line when combined with cisplatin, causing a 52% decrease in IC_{50} .

• APR-246 sensitizes the A2780 cisplatin resistant cell line to cisplatin as evidenced by an increase in cell death.

• Future experiments will aim to replicate and further confirm the occurrence of ferroptosis with the use of iron chelators.

Acknowledgements

This presentation is supported by the Partnership for Careers in Cancer Science and Medicine Summer Experience Program at the University of Texas MD Anderson Cancer Center. Images were produced using BioRender.

Results: APR-246 & Cisplatin

15-30% of patients with OC develop resistance to platinating agents, making re-sensitization imperative. To study the effects of platinum, we used parental and cisplatin resistant A2780 cells.

Cell Viability vs. Cisplatin in Parental A2780

- Cisplatin (IC₅₀= 3.450 uM) \blacksquare Cisplatin+ APR2uM (IC₅₀ = 1.673 uM)





Figure 9. APR-246 overcomes cisplatin resistance in the A2780 cisplatinresistant cell line. n=2, p=0.0052.



Figure 10. There are no detectable changes in nucleotide pool across all A2780 cell lines after treatment with APR-246. Interestingly, (C) the p53 KO and (D) cisplatin resistant cells lines have a higher nucleotide pool compared to the (A) vector and (B) parental cell lines, respectively.

References

Chen, X., Kang, R., Tang, D. 2021. Ferroptosis by Lipid Peroxidation: The Tip of the Iceberg? Front Cell Dev Biol. 9(646890).

Cole, A.J., Dwight, T., Gill A.J., Dickson, K., Zhu, Y., Clarkson, A., Gard, G., Maidens, J., Valmdare, S., Clifton-Bligh, R., Marsh, D. 2016. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci Rep. 6(26191).

Li, L., Qiu, C., Qu, J. 2021. Ferroptosis in Ovarian Cancer: A Novel Therapeutic Strategy Front Oncol. 11(665945).

Mohell, N., Alfredsson, J., Fransson, A., Uustalu, M., Bystrom, S., Gullbo, J., Hallberg, A., Bykov, V.J.N., Bjorklund, U., Wiman, K.G. 2015. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 6(6). Bykov, V.J.N., Zhang, Q., Zhang, M., Ceder, S., Abrahmsen, L., Wiman, K.G. 2016. Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy. Front Oncol. 6(21).